Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial
Open Access
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (1) , 202-209
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHDJournal of Lipid Research, 2009
- Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markersJournal of Lipid Research, 2009
- Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPERAtherosclerosis, 2008
- Comprehensive Lipid Management Versus Aggressive Low-Density Lipoprotein Lowering to Reduce Cardiovascular RiskThe American Journal of Cardiology, 2008
- Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin TreatmentCirculation, 2003
- Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDLJournal of Lipid Research, 2003
- Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of CholesterolNew England Journal of Medicine, 1990